Literature DB >> 2499863

Baculovirus expression of functional P210 BCR-ABL oncogene product.

A M Pendergast1, R Clark, E S Kawasaki, F P McCormick, O N Witte.   

Abstract

The chronic myelogenous leukemia-associated P210 BCR-ABL oncogene protein product has been produced using the baculovirus expression system. High-level expression of the P210 BCR-ABL protein required the removal of GC rich 5' non-coding sequences. P210 BCR-ABL synthesized in insect cells is an active tyrosine protein kinase indistinguishable from P210 BCR-ABL isolated from human cells. Both proteins utilize angiotensin II as a phosphate acceptor in vitro with a Km for ATP of approximately 1.5 microM. P210 BCR-ABL produced in insect cells undergoes autophosphorylation in vitro and in vivo. Gel filtration of P210 BCR-ABL reveals that the protein elutes as a high molecular weight complex of about 800 kD. Approximately 4 to 5 mg of P210 BCR-ABL is produced in one liter of infected insect cells. Following cell disruption and a three-step ion exchange and gel filtration purification procedure, 0.4 mg of soluble P210 BCR-ABL is obtained per liter of suspension culture. An alternative procedure employing detergent extraction and immunoaffinity chromatography gave higher yields and purity from smaller amounts of infected cell extracts. The availability of intact, soluble and enzymatically active P210 BCR-ABL represents a significant advance for studying the biochemical and biophysical properties of the ABL oncogene family of proteins.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2499863

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  The 5' noncoding region of the human leukemia-associated oncogene BCR/ABL is a potent inhibitor of in vitro translation.

Authors:  A J Muller; O N Witte
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

2.  Clonal lymphoid progenitor cell lines expressing the BCR/ABL oncogene retain full differentiative function.

Authors:  P A Scherle; K Dorshkind; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

3.  Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor.

Authors:  A M Pendergast; A J Muller; M H Havlik; R Clark; F McCormick; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

4.  Biochemical characterization of baculovirus-expressed rap1A/Krev-1 and its regulation by GTPase-activating proteins.

Authors:  L A Quilliam; C J Der; R Clark; E C O'Rourke; K Zhang; F McCormick; G M Bokoch
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

5.  The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein.

Authors:  N Takeda; M Shibuya; Y Maru
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

6.  T-cell immunity to the joining region of p210BCR-ABL protein.

Authors:  W Chen; D J Peace; D K Rovira; S G You; M A Cheever
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

7.  A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.

Authors:  J R McWhirter; D L Galasso; J Y Wang
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

8.  Bcr-Abl-mediated protection from apoptosis downstream of mitochondrial cytochrome c release.

Authors:  Paula B Deming; Zachary T Schafer; Jessica S Tashker; Malia B Potts; Mohanish Deshmukh; Sally Kornbluth
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

9.  Structure of 85 kDa subunit of human phosphatidylinositol 3-kinase analyzed by using monoclonal antibodies.

Authors:  S Tanaka; M Matsuda; S Nagata; T Kurata; K Nagashima; Y Shizawa; Y Fukui
Journal:  Jpn J Cancer Res       Date:  1993-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.